rs1114167650

Variant summary

Our verdict is Pathogenic. The variant received 14 ACMG points: 14P and 0B. PM2PP3_StrongPP5_Very_Strong

The NM_000314.8(PTEN):​c.209+5G>A variant causes a splice region, intron change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000142 in 1,410,832 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Pathogenic (★★).

Frequency

Genomes: not found (cov: 32)
Exomes 𝑓: 0.0000014 ( 0 hom. )

Consequence

PTEN
NM_000314.8 splice_region, intron

Scores

1
1
Splicing: ADA: 1.000
2

Clinical Significance

Pathogenic criteria provided, multiple submitters, no conflicts P:5

Conservation

PhyloP100: 9.29

Publications

11 publications found
Variant links:
Genes affected
PTEN (HGNC:9588): (phosphatase and tensin homolog) This gene was identified as a tumor suppressor that is mutated in a large number of cancers at high frequency. The protein encoded by this gene is a phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase. It contains a tensin like domain as well as a catalytic domain similar to that of the dual specificity protein tyrosine phosphatases. Unlike most of the protein tyrosine phosphatases, this protein preferentially dephosphorylates phosphoinositide substrates. It negatively regulates intracellular levels of phosphatidylinositol-3,4,5-trisphosphate in cells and functions as a tumor suppressor by negatively regulating AKT/PKB signaling pathway. The use of a non-canonical (CUG) upstream initiation site produces a longer isoform that initiates translation with a leucine, and is thought to be preferentially associated with the mitochondrial inner membrane. This longer isoform may help regulate energy metabolism in the mitochondria. A pseudogene of this gene is found on chromosome 9. Alternative splicing and the use of multiple translation start codons results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Feb 2015]
PTEN Gene-Disease associations (from GenCC):
  • Cowden syndrome 1
    Inheritance: AD Classification: DEFINITIVE, STRONG, MODERATE Submitted by: Ambry Genetics, Genomics England PanelApp, Labcorp Genetics (formerly Invitae), G2P
  • PTEN hamartoma tumor syndrome
    Inheritance: AD Classification: DEFINITIVE Submitted by: ClinGen
  • macrocephaly-autism syndrome
    Inheritance: AD Classification: STRONG, SUPPORTIVE Submitted by: Ambry Genetics, Genomics England PanelApp, Orphanet
  • renal cell carcinoma
    Inheritance: AD Classification: MODERATE Submitted by: Genomics England PanelApp
  • leiomyosarcoma
    Inheritance: AR Classification: MODERATE Submitted by: Genomics England PanelApp
  • activated PI3K-delta syndrome
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • Bannayan-Riley-Ruvalcaba syndrome
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • Cowden disease
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • Lhermitte-Duclos disease
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • Proteus-like syndrome
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • glioma susceptibility 2
    Inheritance: AD Classification: LIMITED Submitted by: Ambry Genetics

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Pathogenic. The variant received 14 ACMG points.

PM2
Very rare variant in population databases, with high coverage;
PP3
Splicing predictors support a deleterious effect. Scorers claiming Pathogenic: dbscSNV1_ADA, dbscSNV1_RF, max_spliceai. No scorers claiming Uncertain. No scorers claiming Benign.
PP5
Variant 10-87925562-G-A is Pathogenic according to our data. Variant chr10-87925562-G-A is described in ClinVar as Pathogenic. ClinVar VariationId is 427614.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
PTENNM_000314.8 linkc.209+5G>A splice_region_variant, intron_variant Intron 3 of 8 ENST00000371953.8 NP_000305.3
PTENNM_001304717.5 linkc.728+5G>A splice_region_variant, intron_variant Intron 4 of 9 NP_001291646.4
PTENNM_001304718.2 linkc.-541-5484G>A intron_variant Intron 2 of 8 NP_001291647.1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
PTENENST00000371953.8 linkc.209+5G>A splice_region_variant, intron_variant Intron 3 of 8 1 NM_000314.8 ENSP00000361021.3

Frequencies

GnomAD3 genomes
Cov.:
32
GnomAD4 exome
AF:
0.00000142
AC:
2
AN:
1410832
Hom.:
0
Cov.:
29
AF XY:
0.00000142
AC XY:
1
AN XY:
703524
show subpopulations
⚠️ The allele balance in gnomAD version 4 Exomes is significantly skewed from the expected value of 0.5.
African (AFR)
AF:
0.00
AC:
0
AN:
32432
American (AMR)
AF:
0.00
AC:
0
AN:
44082
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
25678
East Asian (EAS)
AF:
0.00
AC:
0
AN:
39242
South Asian (SAS)
AF:
0.00
AC:
0
AN:
84542
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
46968
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
5622
European-Non Finnish (NFE)
AF:
0.00000186
AC:
2
AN:
1073462
Other (OTH)
AF:
0.00
AC:
0
AN:
58804
⚠️ The allele balance in gnomAD4 Exomes is highly skewed from 0.5 (p-value = 0.000203476), which strongly suggests a high chance of mosaicism in these individuals.
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.375
Heterozygous variant carriers
0
0
1
1
2
2
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
Cov.:
32
Alfa
AF:
0.000128
Hom.:
0

ClinVar

Significance: Pathogenic
Submissions summary: Pathogenic:5
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not provided Pathogenic:2
Nov 17, 2020
GeneDx
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Intronic +5 splice site variant demonstrated to result in an in-frame deletion of exon 3, disrupting the critical phosphatase domain and ATP binding motifs (Agarwal 2005, Lobo 2009, Molinari 2014, Chen 2017); Not observed in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 22595938, 10340391, 23695273, 25525159, 31336731, 31784482, 16014636, 18626099, 11071384, 28315423, 32959437, 10232405, 9467011, 20712882, 23335809, 28677221, 19457929, 24475377, 32885271)

Department of Pathology and Laboratory Medicine, Sinai Health System
Significance:Pathogenic
Review Status:no assertion criteria provided
Collection Method:clinical testing

The PTEN c.209+5G>A variant was identified in 6 of 238 proband chromosomes (frequency: 0.0252) from individuals or families with Cowden syndrome and Bannayan–Zonana syndrome (Celebi_1999, Chen_2017, Marsh_1998, Plamper_2017). The variant was also identified in dbSNP (ID: rs1114167650) as “With Pathogenic allele”, ClinVar (as pathogenic by Ambry Genetics and Cleveland Clinic), Clinvitae (2x as in ClinVar), Cosmic (found as a somatic mutation 3 x in the central nervous system, 2 x in the endometrium, 1 x in the lung and 1 x in the kidney), LOVD 3.0 (2x as pathogenic), and Zhejiang Colon Cancer Database (1 x). The variant was not identified in the MutDB database. The variant was not identified in the following control databases: the 1000 Genomes Project, the NHLBI GO Exome Sequencing Project, the Exome Aggregation Consortium (August 8th 2016), or the Genome Aggregation Database (Feb 27, 2017). A functional study showed the c.209+5G>A variant led to the splicing out of exon 3 in two different patients affected with Cowden syndrome (Agrawal_2005). A microarray study of gene expression analysis in 74 tumours from patients with familial breast cancer found the variant in 4 tumours (Banneau_2010). The variant has also been reported in adolescents with PTEN hamartoma tumour syndrome (Plamper_2017) and in a patient with glioblastoma (Rickert_2009). The c.209+5G>A variant is located in the 5' splice region but does not affect the invariant +1 and +2 positions. However, positions +3 to +6 are part of the splicing consensus sequence and variants involving these positions sometimes affect splicing. In addition, 5 of 5 in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) predict a greater than 10% difference in splicing. In summary, based on the above information this variant meets our laboratory’s criteria to be classified as pathogenic.

Cowden syndrome 1 Pathogenic:1
May 26, 2017
Cancer Genomic Medicine Translational Research Lab, Cleveland Clinic Genomic Medicine Institute
Significance:Pathogenic
Review Status:no assertion criteria provided
Collection Method:research

PTEN hamartoma tumor syndrome Pathogenic:1
Oct 23, 2024
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This sequence change falls in intron 3 of the PTEN gene. It does not directly change the encoded amino acid sequence of the PTEN protein. RNA analysis indicates that this variant induces altered splicing and likely results in a shortened protein product. This variant is not present in population databases (gnomAD no frequency). This variant has been observed in individuals with PTEN-related conditions (PMID: 10232405, 20712882, 23695273; internal data). This variant is also known as IVS3+5G>A. ClinVar contains an entry for this variant (Variation ID: 427614). Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Studies have shown that this variant results in skipping of exon 3, but is expected to preserve the integrity of the reading-frame (PMID: 16014636, 28677221). For these reasons, this variant has been classified as Pathogenic.

Hereditary cancer-predisposing syndrome Pathogenic:1
Jan 03, 2025
Ambry Genetics
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

The c.209+5G>A intronic pathogenic mutation results from a G to A substitution 5 nucleotides after coding exon 3 in the PTEN gene. This alteration has been reported in individuals with clinical features of PTEN hamartoma tumor syndrome (PHTS) and was found to segregate with disease in both Cowden syndrome as well as Bannayan-Riley-Ruvalcaba syndrome families (Marsh DJ et al. Hum Mol Genet. 1998;7(3):507-515; Celebi J et al. Exp Dermatol. 1999 Apr;8(2):134-9; Nizialek EA et al. Eur. J. Hum. Genet. 2015 Nov;23:1538-43; Plamper M et al. Cancers (Basel), 2019 Jul;11). This alteration was also described in four Cowden patients with breast apocrine carcinoma (Banneau G et al. Breast Cancer Res. 2010; 12(4):R63). In addition, RNA studies demonstrated in-frame exon 3 skipping for this variant, which was reported to result in reduced PTEN phosphatase activity in one study (Agrawal S et al. Hum Mol Genet. 2005;14(16):2459-2468; Chen HJ et al. Hum. Mutat. 2017 10;38:1372-137; Ambry internal data). Of note, this mutation has been referred to as IVS3+5G>A in some literature. Based on the available information, this alteration is classified as a disease-causing mutation.

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.18
CADD
Benign
23
DANN
Uncertain
0.98
PhyloP100
9.3
Mutation Taster
=3/97
disease causing (ClinVar)

Splicing

Name
Calibrated prediction
Score
Prediction
dbscSNV1_ADA
Pathogenic
1.0
dbscSNV1_RF
Pathogenic
1.0
SpliceAI score (max)
0.99
Details are displayed if max score is > 0.2
DS_DL_spliceai
0.99
Position offset: -5

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs1114167650; hg19: chr10-89685319; API